MedTrace Logo

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

NCT07264998 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-04-03

No results posted yet for this study

Summary

Why is this study being done? Many patients with a type of breast cancer (called HR-positive) take a medicine called Abemaciclib. While this medicine is effective, a very common side effect is diarrhea, which can be severe enough to disrupt treatment and reduce quality of life. The reason why some patients get diarrhea and others do not is not well understood. This study aims to investigate whether the natural bacteria living in the gut (known as the gut microbiome) play a role in this side effect. Researchers will compare the gut bacteria of patients who develop diarrhea with those who do not.

What will happen in the study? This is an observational study, which means that patients will receive their normal cancer treatment and will not be given any new or experimental drugs as part of this initial phase.

* Patients who are already being treated with Abemaciclib will be invited to join.
* They will be placed into one of two groups: those who experience diarrhea and those who do not.
* Participants will be asked to provide stool (feces) samples and may also provide optional blood samples at specific times during their treatment.
* Researchers will analyze these samples in the lab to study the types and functions of the gut bacteria.

Who can participate?

* Adult women (aged 18-75) diagnosed with HR-positive breast cancer.
* Currently receiving treatment with Abemaciclib for at least 2 weeks.
* Must be willing to provide informed consent and follow the study procedures.

What are the potential benefits? Participants will not receive any direct medical benefit from taking part in this study. However, the information learned may help researchers better understand why diarrhea occurs and, in the future, could lead to new ways to prevent or treat this side effect for other cancer patients.

How is privacy protected? All personal information and samples collected will be de-identified using a unique code. This means that the data used for analysis cannot be directly linked back to the participant's identity. All data is stored securely according to strict ethical guidelines.

Conditions

Sponsors & Collaborators

  • Hubei Cancer Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-21
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264998 on ClinicalTrials.gov